Cosmo Pharmaceuticals NV
SIX:COPN
Cosmo Pharmaceuticals NV
SIX:COPN
Price:
85.5
CHF
-1.72%
Market Cap:
CHf1.5B
Relative Value
The Relative Value of one
COPN
stock under the Base Case scenario is
47.93
CHF.
Compared to the current market price of 85.5 CHF,
Cosmo Pharmaceuticals NV
is
Overvalued by 44%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
COPN
Relative Value
Base Case
47.93
CHF
Overvaluation 44%
Multiples Across Competitors
COPN Competitors Multiples
Cosmo Pharmaceuticals NV Competitors
Cosmo Pharmaceuticals NV Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IE |
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
1.4B CHF | 8.3 | 27.3 | 19 | 22.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
934.5B USD | 14.3 | 45.3 | 30.5 | 32.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.6B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
257.3B CHF | 4.2 | 19.9 | 11.8 | 13.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.5B GBP | 5.1 | 29.2 | 16.2 | 22.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.6B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
285.6B USD | 4.4 | 15.6 | 9.7 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.3B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
